Many in vitro studies have clearly demonstrated that some p53 mutants can acquire new functions, thereby contributing actively to the tumor initiation, progression and the increased resistance to conventional anticancer treatments.3, 10, 11, 12, 13 Indeed, mice knocked in with mutant p53-R270H or p53-R172H, corresponding to the human hotspot p53-R273H and p53-R175H mutants, respectively, developed highly metastatic tumors compared with p53-null mice, supporting the notion of gain-of-function properties acquired by mutant p53.14, 15, 16, 17, 18, 19. This evidence concerns the gene TP53 and neoplasm.